Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | TSPO | P30536 | 3/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16682370 | 0.87 | RCE1 (0.47) | MAPTGFERLMNA | |
| SCHEMBL18067982 | 0.83 | ALOX5 (0.44) | ALDH1A1TSHRTDP1KDM4ESMN1; SMN2 | |
| SCHEMBL14412216 | 0.82 | ALDH1A1 (0.59) | MAPTALDH1A1GFERKDM4EMEN1 | |
| SCHEMBL9416644 | 0.81 | ALDH1A1 (0.50) | ALDH1A1CYP3A4KDM4ELMNACHRM2 | |
| SCHEMBL28780453 | 0.80 | MAPT (0.42) | MAPTALDH1A1GFERCYP3A4TSHR | |
| SCHEMBL6414624 | 0.79 | MEN1 (0.56) | ALDH1A1LMNANPSR1SLC2A1MEN1 | |
| SCHEMBL6078000 | 0.79 | LMNA (0.55) | MAPTALDH1A1TDP1LMNAMEN1 | |
| SCHEMBL18068879 | 0.79 | CETP (0.43) | MAPTALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL2117209 | 0.78 | LMNA (0.62) | ALDH1A1TSHRTDP1KDM4ELMNA | |
| SCHEMBL2218290 | 0.78 | KMT2A (0.59) | MAPTALDH1A1GFERCYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023530-B2 | Diamine, polyamic acid, and polyimide | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-07-17 | — | — | US | disclosed |
| US-20160264520-A1 | NOVEL DIAMINE, POLYAMIC ACID, AND POLYIMIDE | NISSAN CHEMICAL INDUSTRIES. LTD. (JP) | 2016-09-15 | — | — | US | disclosed |
| US-9278922-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278922-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278922-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-03-08 | — | — | US | disclosed |
| EP-2419404-B1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2419404-A1 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010120935-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010120935-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20100267634-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267634-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267634-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267634-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | MAPT 2833/4885ALDH1A1 2858/4885GFER 3767/4885 |
| US-10023530-B2 | Diamine, polyamic acid, and polyimide | H1-2, H1-4, H1-0 | MAPT 3277/4885ALDH1A1 1921/4885GFER 2145/4885 |
| US-20160264520-A1 | NOVEL DIAMINE, POLYAMIC ACID, AND POLYIMIDE | H1-4, H1-2, H1-5 | MAPT 3086/4885ALDH1A1 1919/4885GFER 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.